[Skip to Content]
Sign In
Individual Sign In
Create an Account
Institutional Sign In
OpenAthens Shibboleth
Purchase Options:
[Skip to Content Landing]
Views 2,085
Citations 0
In This Issue of JAMA
January 9, 2018


JAMA. 2018;319(2):103-105. doi:10.1001/jama.2017.12185

In a prior study, idalopirdine added to donepezil improved cognitive performance in patients with moderate Alzheimer disease (AD) dementia. To confirm or refute these initial findings, Atri and colleagues conducted 3 randomized trials in 2525 patients with mild to moderate AD and found that idalopirdine did not improve cognition over 24 weeks of treatment. In an Editorial, Bennett suggests that delaying the onset of dementia may have a greater impact on population health than treating AD once it has become symptomatic.

First Page Preview View Large
First page PDF preview
First page PDF preview